98%
921
2 minutes
20
Objective: Tissue abnormalities in focal epilepsy may extend beyond the presumed focus. The underlying pathophysiology of these broader changes is unclear, and it is not known whether they result from ongoing disease processes or treatment-related side effects, or whether they emerge earlier. Few studies have focused on the period of onset for most focal epilepsies, childhood. Fewer still have utilized quantitative magnetic resonance imaging (MRI), which may provide a more sensitive and interpretable measure of tissue microstructural change. Here, we aimed to determine common spatial modes of changes in cortical architecture in children with heterogeneous drug-resistant focal epilepsy and, secondarily, whether changes were related to disease severity.
Methods: To assess cortical microstructure, quantitative T1 and T2 relaxometry (qT1 and qT2) was measured in 43 children with drug-resistant focal epilepsy (age range = 4-18 years) and 46 typically developing children (age range = 2-18 years). We assessed depth-dependent qT1 and qT2 values across the neocortex, as well as their gradient of change across cortical depths. We also determined whether global changes seen in group analyses were driven by focal pathologies in individual patients. Finally, as a proof-of-concept, we trained a classifier using qT1 and qT2 gradient maps from patients with radiologically defined abnormalities (MRI positive) and healthy controls, and tested whether this could classify patients without reported radiological abnormalities (MRI negative).
Results: We uncovered depth-dependent qT1 and qT2 increases in widespread cortical areas in patients, likely representing microstructural alterations in myelin or gliosis. Changes did not correlate with disease severity measures, suggesting they may represent antecedent neurobiological alterations. Using a classifier trained with MRI-positive patients and controls, sensitivity was 71.4% at 89.4% specificity on held-out MRI-negative patients.
Significance: These findings suggest the presence of a potential imaging endophenotype of focal epilepsy, detectable irrespective of radiologically identified abnormalities.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7616339 | PMC |
http://dx.doi.org/10.1111/epi.17861 | DOI Listing |
Epileptic Disord
September 2025
APHM, Timone Hospital, Epileptology and Cerebral Rhythmology, Marseille, France.
This case study reports the first documented use of stereoelectroencephalography (SEEG)-guided radiofrequency thermocoagulation (RFTC) to treat refractory status epilepticus (RSE). A 33-year-old woman with drug-resistant epilepsy and recurrent RSE underwent SEEG to define her epileptogenic zone. A new RSE started shortly before and continued during the SEEG exploration, being unresponsive to multiple antiseizure medications, vagal nerve stimulation, and corticosteroid therapy.
View Article and Find Full Text PDFBiomed Rep
November 2025
Department of Pediatric Neurology, King Fahad Specialist Hospital, Dammam 31444, Saudi Arabia.
Intraoperative electrocorticography (ECoG) represents a crucial tool for improving seizure outcomes during epilepsy surgeries by assisting in localization of the epileptogenic zones. There is a shortage of information in the literature regarding single-center experiences and long-term outcomes after ECoG-guided surgeries. Data are particularly scarce from the Eastern Mediterranean Region.
View Article and Find Full Text PDFAlpha Psychiatry
August 2025
Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, 130021 Changchun, Jilin, China.
Background: The progressive legalization and widespread use of cannabis has led to its use as a treatment for certain neuropsychiatric disorders. Traditional epidemiological studies suggest that cannabis use has an effect on some neurocognitive aspects. However, it is unclear whether cannabis use is causally related to common neuropsychiatric disorders.
View Article and Find Full Text PDFFront Pharmacol
August 2025
Unidad de Investigación Médica en Enfermedades Neurológicas, Hospital de Especialidades, "Dr. Bernardo Sepúlveda", Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico.
Background: Cannabidiol (CBD) reduces the frequency of seizures in individuals with specific epileptic syndromes, but its effectiveness for other types of drug-resistant epilepsy (DRE) is unclear. CYP450 enzymes primarily metabolize CBD. The aim of this study was to identify CYP450 genotypes regarding the response of CBD treatment concomitant with anti-seizure drugs in patients with DRE.
View Article and Find Full Text PDFBrain Commun
August 2025
Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford OX3 9DU, UK.
Understanding the cognitive trajectory of a neurological disease can provide important insight on underlying mechanisms and disease progression. Cognitive impairment is now well established as beginning many years before the diagnosis of Alzheimer's disease, but pre-diagnostic profiles are unclear for other neurological conditions that may be associated with cognitive impairment. We analysed data from the prospective UK Biobank cohort with study baseline assessment performed between 2006 and 2010 and participants followed until 2021.
View Article and Find Full Text PDF